DPPIV inhibitors extend GLP-2 mediated tumour promoting effects on intestinal cancer cells

  title={DPPIV inhibitors extend GLP-2 mediated tumour promoting effects on intestinal cancer cells},
  author={Kai Masur and Fletcher Schwartz and Frank Entschladen and Bernd Niggemann and K. S. Zaenker},
  journal={Regulatory Peptides},

Glucagon-like peptide-2 does not modify the growth or survival of murine or human intestinal tumor cells.

Although GLP-2R activation engages signaling pathways promoting cell proliferation and cytoprotection in the normal gut epithelium, sustained direct or indirect modulation of GLP -2R signaling does not modify intestinal tumor cell growth or survival.

Role of Glucagon-like Peptide-2 in Rodent Models of Colon Cancer

Findings indicate a procarcinogenic role for both exogenous and endogenous GLP-2, which is an intestinotrophic and intestinal antiinflammatory hormone in rodents and appears to increase the occurrence of intestinal tumours.

Does DPP-IV Inhibition Offer New Avenues for Therapeutic Intervention in Malignant Disease?

The modulation of the bioavailability and function of other DPP-IV substrates, including chemokines, raises the possibility that the use of these orally administered drugs with favorable side-effect profiles might be extended beyond the treatment of hyperglycemia.

Role of DPP IV Inhibitor in Type-2 Diabetes Mellitus

As the insulinotropic action of GLP-1 is preserved in type 2 diabetic patients, this peptide was likely to be developed s a therapeutic agent for this disease.

Growth factor based therapies and intestinal disease: is glucagon-like peptide-2 the new way forward?

Glucagon like peptide-2 and neoplasia; a systematic review

This systematic review indicated that treatment with GLP-2(1–33) up to 30 months in humans without any known pre-existing cancer did not confer an increased risk of intestinal neoplasia in patients or animals.

GLP-2 receptors in human disease: High expression in gastrointestinal stromal tumors and Crohn’s disease

Cardiovascular Benefits of Native GLP-1 and its Metabolites: An Indicator for GLP-1-Therapy Strategies

This review attempts to differentiate the cardiovascular effects between 7-36a and 9- 36a in order to provide new insights into GLP-1 physiology, and facilitate the efforts to develop a superior GLp-1-therapy strategy for T2DM and cardiovascular diseases.



Glucagon-like peptide 2 (GLP-2) accelerates the growth of colonic neoplasms in mice

The present results clearly indicate that GLP-2 promotes the growth of mucosal neoplasms and highlight the need for future investigations on the effects of GLp-2 in conditions needing long time treatment or with increased gastrointestinal cancer susceptibility.

Glucagon-Like Peptide 2 Stimulates Intestinal Epithelial Proliferation In Vitro

It is suggested that GLP-2 acts directly on human intestinal epithelial cells to stimulate their proliferation, as measured by increased [3H]thymidine incorporation into cellular DNA.

Nutrient-stimulated GLP-2 release and crypt cell proliferation in experimental short bowel syndrome.

Glucagon-like peptide-2 is an enteroendocrine peptide that is released in response to luminal nutrients and has unique trophic actions in the gastrointestinal tract and may be important in controlling intestinal adaptation.

Dipeptidyl peptidase inhibitors as new drugs for the treatment of type 2 diabetes

Based on their mode of action, DPP-IV inhibitors seem to be of particular value in early forms of type 2 diabetes, either alone or in combination with other types of oral agents.

Glucagon-like peptide (GLP)-2 reduces chemotherapy-associated mortality and enhances cell survival in cells expressing a transfected GLP-2 receptor.

It is demonstrated that the antiapoptotic effects of GLP-2 on intestinal crypt cells may be useful for the attenuation of chemotherapy-induced intestinal mucositis.

Teduglutide ([Gly2]GLP‐2) protects small intestinal stem cells from radiation damage

The results suggest that teduglutide has the ability to modulate clonogenic stem cell survival in the small intestine and this may have a useful clinical application in the prevention of cancer therapy‐induced mucositis.

Glucagon-like peptide 2: a nutrient-responsive gut growth factor.

Based on its efficacy in preventing atrophy and stimulating growth in the neonatal gut, GLP-2 may be a promising therapeutic adjuvant for treatment of infants with compromised gut function.

Glucagon-like peptide 2.

  • D. Drucker
  • Biology, Medicine
    The Journal of clinical endocrinology and metabolism
  • 2001
The cytoprotective, reparative, and energy-retentive properties of GLp-2 suggests that GLP-2 may potentially be useful for the treatment of human disorders characterized by injury and/or dysfunction of the intestinal mucosal epithelium.

Glucagon-like peptide-2 enhances intestinal epithelial barrier function of both transcellular and paracellular pathways in the mouse.

GLP-2 enhances intestinal epithelial barrier function by affecting both paracellular and transcellular pathways and thus may be of therapeutic value in a number of gastrointestinal conditions.